Guangdong Silver Age Sci & Tech Co (300221) Fair Value & Analysis
Basic Materials · CN · Market cap 8.1B CNY
Analysis
Guangdong Silver Age Sci & Tech Co (300221) currently trades at ¥17.62, while our model-based Fair Value estimate is ¥3.73 — implying the stock looks roughly 78.8% overvalued today. We read business quality at 93/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Guangdong Silver Age Sci & Tech Co.,Ltd. engages in the research, development, production, and sale of polymer materials in China. The company's principal products include PC, PP, ABS, PC/ABS alloy, PA, PBT, PET, PPS, PVC/ABS alloy, packaging materials, flame retardant resins, reinforced toughening resins, plastic alloys, functional masterbatches, and other categories as well as recyclable, new energy, consumer electronics and 5G, 3D printing, electronic chemicals, smart lighting, medical, degradable, automobiles and smart home materials. Its products are used in household appliances, modern agriculture, rail transportation, aircraft, aerospace, equipment, communications, electronics and electrical and architectural decoration, and new household service robots. The company was formerly known as Dongguan Silver Age Plastics Co., Ltd and changed its name to Guangdong Silver Age Sci & Tech Co.,Ltd. in December 2006. The company was founded in 1997 and is headquartered in Dongguan, China.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.